Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Familial Cancer|January 5, 2019
TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohortJ J Bakhuizen, F B Hogervorst, M E Velthuizen, et al.The Journal of Pathology|October 18, 2023
Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomasCjh Kramer, L Lanjouw, D Ruano, et al.Journal of Medical Genetics|September 6, 2005
Cancer risks in BRCA2 families: estimates for sites other than breast and ovaryC J van Asperen, R M Brohet, E J Meijers-Heijboer, et al.Breast Cancer Research and Treatment|February 29, 2012
Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testingK De Leeneer, M Van Bockstal, S De Brouwer, et al.Journal of the National Cancer Institute|March 20, 2015
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reductionB A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, et al.Clinical Genetics|June 8, 2017
Performance of BRCA1/2 mutation prediction models in male breast cancer patientsS Moghadasi, V Grundeken, L A M Janssen, et al.British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.Gynecologic Oncology|May 6, 2015
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Antoinette Hollestelle, Frederieke H van der Baan, et al.Pageof 4